德視佳(01846.HK)首兩個月眼科手術總數按年增7.2%
德視佳(01846.HK)公布,儘管受到全球範圍內COVID-19疫情反復的影響,集團今年首兩個月進行的眼科手術總數為4,401宗,超過去年同期進行的眼科手術總數,增加約7.2%。
另外,首兩個月集團進行的屈光性激光手術為2,229宗,較去年同期增加約14.3%。晶體置換手術為1,732宗,增加約6.8%。
集團指,自今年年初以來,中國出現變種病毒Omicron,蔓延至一些集團經營業務涉及的主要城市,包括上海、深圳、北京及杭州。疫情廣泛爆發引致政府採取嚴格的公共衛生措施,包括大規模檢測、區域封鎖及差旅限制,預期將對集團的業務營運產生一定的可控影響。然而,集團在中國的整體業務正常,突發公共衛生事件及公共政策變動應該不會對集團造成重大影響。至於集團於德國、丹麥及英國的業務尚未受到疫情的重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.